43 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
relevant to neurological diseases.
“We are very pleased to partner with a global pharmaceutical company like GSK with an ambitious innovation agenda … relationships like this one and they have a history of successfully working with others to access innovation and deliver next-generation transformational
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
20 Oct 20
Results of Operations and Financial Condition
10:52am
Exhibit 99.1 INVESTOR & ANALYST DAY INNOVATION DRIVING VALUE OCTOBER 20, 2020 Nasdaq:1 LGND Copyright © 2020 Ligand. All Rights Reserved.
2 SAFE … PEOPLE & TECHNOLOGY INNOVATION INNOVATION DRIVING VALUE Superior support and High growth and strong cash engagement with pharmaceutical flows; projected
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
12 Mar 19
Regulation FD Disclosure
10:02am
-based Drugs Over 70 YES Complex Drug Over 20 YES Targets Formulation & Drug Stability Over 56 YES Drug Targeting in the Body Over 6 YES
29 Innovation … 2008 2010 2012 2014 2016 2018 29
30 Innovation and Potential Ligand’s Technology Platform for Delivery of Drugs to the Liver Diseases of the liver
8-K
EX-99
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
12 Apr 02
Other events
12:00am
, a leading innovation-driven corporation, is developing a growing
portfolio of best-in-class pharmaceutical products by applying the latest
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Jun 11
Regulation FD Disclosure
12:00am
patent portfolio providing protection
through 2029
Trade secrets, Drug Master File
Continuing internal innovation
Captisol
Enabling New Drugs …
Captisol-
enabled
development
programs
with potential
for high
returns
Captisol
The Value
Reformulation can bring meaningful innovation
8-K
EX-99.1
m2wh0 gwjjd1chvndz
23 Jun 11
Regulation FD Disclosure
12:00am
8-K
EX-99.1
f3m ahiiuzy
8 Aug 11
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
425
EX-99.1
x4c55otfdyyfpyo2ek0l
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.1
vqzvbp4szfm4czvyu
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.3
4756xd c7xgvq
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
425
EX-99.3
qxvnj
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.1
rssshvdeb4u
2 May 19
Ligand Reports First Quarter 2019 Financial Results
4:09pm
8-K
EX-99.1
h1pmpz
30 Jul 19
Ligand Reports Second Quarter 2019 Financial Results
8:13am
8-K
EX-99.1
0j3ua0hpp
5 Nov 19
Ligand Reports Third Quarter 2019 Financial Results
4:05pm
8-K
EX-99.1
ocu0oyonikrzmtdj
18 Nov 14
Regulation FD Disclosure
12:00am
425
EX-99.1
t3z8zcaya rz
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
fx1ob10mn4ptfpt2x v7
21 Jun 22
Regulation FD Disclosure
6:19am